Real-world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study.
Intraocular inflammation occurred in 0.13% of real-world faricimab injections.
Real-world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study.
To estimate the real-world incidence of intraocular inflammation (intraocular inflammation) following intravitreal faricimab injections at a large, highly specialized tertiary centre.
To estimate the real-world incidence of intraocular inflammation (intraocular inflammation) following intravitreal faricimab injections at a large, highly specialized tertiary centre.
Single-centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024.
eye inflammation was rare per injection given
Intraocular inflammation occurred after a median of 4 faricimab injections (IQR: 2, range: 1-9) and a median of 8.5 days (IQR: 20, range: 0-37) after the last injection.
The median disease duration (time from diagnosis to resolution) was 32 days (IQR: 46, range: 6-144).
Eighty per cent of patients who developed intraocular inflammation were females, and females had 2.42-2.66 times higher hazard of developing intraocular inflammation than males.
All panuveitis cases (n = 6) underwent vitrectomy, and one had a positive culture, yielding a 0.003% per-injection incidence of culture-positive endophthalmitis.
Faricimab demonstrated an acceptable safety profile in our study. The incidence of intraocular inflammation events was consistent with those observed in other real-world reports.
The intraocular inflammation events showed a female predominance, varied presentations and durations, but generally had favourable outcomes.